dysesthesia


Also found in: Medical, Wikipedia.

dysesthesia

an impaired condition of any of the senses.
See also: Perception
Translations

dys·es·the·si·a

n. disestesia, reacción excesiva de molestia a algunas sensaciones que por lo común no producen dolor.
Mentioned in ?
References in periodicals archive ?
The presentation of calcific uremic arteriolopathy in the early stages is typically with dysesthesia, progressing to an erythematous, violaceous rash similar to livedo reticularis.
Restless leg syndrome (RLS) is a condition generally characterized by dysesthesia or paresthesia of the legs, motor restlessness, and an intense urge to move (Douglas, 2002).
Ganglio-neuropathy is a syndrome characterized by a symmetric/asymmetric involvement of sensorial components, diminishing or disappearance of reflexes, ataxia, glove- and stocking-type pain, and dysesthesia.
paresthesia, dysesthesia, pain) were observed in 5.
Symptoms include aphasia, apraxia, dysesthesia, cognitive abnormalities, and occasionally even headache or seizures.
Restless legs syndrome (RLS) is characterized by dysesthesia in the legs which is usually described as "pins and needles" or a "creepy and crawly" sensation in the legs that is only relieved with movement.
By day two his right sided upper extremity dysesthesia had resolved and the left side hyperesthesia had diminished.
Chemotherapy-Induced Peripheral neuropathy Characteristics Sensory Symptoms * Paresthesia * Hyperesthesia * Hypoesthesia * Dysesthesia * Pain * Numbness and tingling * Hyporeflexia or areflexia * Diminished or absent proprioception, vibratory sensation, cutaneous sensation, or sense of sharp or dull discrimination Motor Symptoms * Weakness * Gait disturbance * Balance disturbance * Difficulty with fine motor skills (e.
The most common presenting symptom of all extracranial schwannomas is a painless neck mass; patients with a trigeminal schwannoma may also demonstrate facial dysesthesia.
3,4) It represents reversible palm and sole acral erythema, accompanied by various degrees of dysesthesia and epidermal desquamation at the pressure points, and is seen in approximately 30% of patients taking sorafenib.